company background image

Mirum Pharmaceuticals NasdaqGM:MIRM Stock Report

Last Price


Market Cap







03 Jul, 2022


Company Financials +
MIRM fundamental analysis
Snowflake Score
Future Growth5/6
Past Performance0/6
Financial Health4/6

MIRM Stock Overview

Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases.

Mirum Pharmaceuticals Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Mirum Pharmaceuticals
Historical stock prices
Current Share PriceUS$19.98
52 Week HighUS$28.65
52 Week LowUS$12.82
1 Month Change-20.81%
3 Month Change-16.99%
1 Year Change19.28%
3 Year Changen/a
5 Year Changen/a
Change since IPO51.25%

Recent News & Updates

May 27

Mirum Pharmaceuticals: Post-Approval Execution Looks Excellent

Mirum's maralixibat was approved in September. The company looks like it is executing very well. I am waiting for dips to buy back in.

Shareholder Returns

MIRMUS BiotechsUS Market

Return vs Industry: MIRM exceeded the US Biotechs industry which returned -25.1% over the past year.

Return vs Market: MIRM exceeded the US Market which returned -21.2% over the past year.

Price Volatility

Is MIRM's price volatile compared to industry and market?
MIRM volatility
MIRM Average Weekly Movement9.7%
Biotechs Industry Average Movement13.2%
Market Average Movement8.1%
10% most volatile stocks in US Market16.9%
10% least volatile stocks in US Market3.3%

Stable Share Price: MIRM is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 10% a week.

Volatility Over Time: MIRM's weekly volatility (10%) has been stable over the past year.

About the Company

2018144Chris Peetz

Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. The company’s lead product candidate is LIVMARLI, an investigational oral drug for the treatment of progressive familial intrahepatic cholestasis disease, as well as for the treatment of Alagille syndrome and biliary atresia disease. It also develops Volixibat drug for treatment of intrahepatic cholestasis of pregnancy and primary sclerosing cholangitis.

Mirum Pharmaceuticals Fundamentals Summary

How do Mirum Pharmaceuticals's earnings and revenue compare to its market cap?
MIRM fundamental statistics
Market CapUS$636.19m
Earnings (TTM)-US$70.06m
Revenue (TTM)US$32.03m


P/S Ratio


P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
MIRM income statement (TTM)
Cost of RevenueUS$4.33m
Gross ProfitUS$27.70m
Other ExpensesUS$97.77m

Last Reported Earnings

Mar 31, 2022

Next Earnings Date


Earnings per share (EPS)-2.20
Gross Margin86.49%
Net Profit Margin-218.74%
Debt/Equity Ratio0%

How did MIRM perform over the long term?

See historical performance and comparison
We’ve recently updated our valuation analysis.


Is MIRM undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score


Valuation Score 3/6

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • PEG Ratio

Key Valuation Metric

Which metric is best to use when looking at relative valuation for MIRM?

Other financial metrics that can be useful for relative valuation.

MIRM key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue15.6x
Enterprise Value/EBITDA-3.2x
PEG Ration/a

Price to Sales Ratio vs Peers

How does MIRM's PS Ratio compare to its peers?

MIRM PS Ratio vs Peers
The above table shows the PS ratio for MIRM vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPSEstimated GrowthMarket Cap
Peer Average116.7x
VNDA Vanda Pharmaceuticals
GERN Geron
SGMO Sangamo Therapeutics
ORGO Organogenesis Holdings
MIRM Mirum Pharmaceuticals

Price-To-Sales vs Peers: MIRM is good value based on its Price-To-Sales Ratio (19.9x) compared to the peer average (116.7x).

Price to Earnings Ratio vs Industry

How does MIRM's PE Ratio compare vs other companies in the US Biotechs Industry?

Price-To-Sales vs Industry: MIRM is expensive based on its Price-To-Sales Ratio (19.9x) compared to the US Biotechs industry average (13.2x)

Price to Sales Ratio vs Fair Ratio

What is MIRM's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

MIRM PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio19.9x
Fair PS Ratio13.8x

Price-To-Sales vs Fair Ratio: MIRM is expensive based on its Price-To-Sales Ratio (19.9x) compared to the estimated Fair Price-To-Sales Ratio (13.8x).

Share Price vs Fair Value

What is the Fair Price of MIRM when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: MIRM ($19.98) is trading below our estimate of fair value ($264.8)

Significantly Below Fair Value: MIRM is trading below fair value by more than 20%.

Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate MIRM's PEG Ratio to determine if it is good value.

Discover undervalued companies

Future Growth

How is Mirum Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 7 analysts?

Future Growth Score


Future Growth Score 5/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings vs Savings Rate: MIRM is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1.9%).

Earnings vs Market: MIRM is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: MIRM is expected to become profitable in the next 3 years.

Revenue vs Market: MIRM's revenue (48.5% per year) is forecast to grow faster than the US market (8.2% per year).

High Growth Revenue: MIRM's revenue (48.5% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: MIRM is forecast to be unprofitable in 3 years.

Discover growth companies

Past Performance

How has Mirum Pharmaceuticals performed over the past 5 years?

Past Performance Score


Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: MIRM is currently unprofitable.

Growing Profit Margin: MIRM is currently unprofitable.

Past Earnings Growth Analysis

Earnings Trend: MIRM is unprofitable, and losses have increased over the past 5 years at a rate of 31.9% per year.

Accelerating Growth: Unable to compare MIRM's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: MIRM is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (98.2%).

Return on Equity

High ROE: MIRM has a negative Return on Equity (-64.32%), as it is currently unprofitable.

Discover strong past performing companies

Financial Health

How is Mirum Pharmaceuticals's financial position?

Financial Health Score


Financial Health Score 4/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: MIRM's short term assets ($155.3M) exceed its short term liabilities ($34.6M).

Long Term Liabilities: MIRM's short term assets ($155.3M) exceed its long term liabilities ($134.7M).

Debt to Equity History and Analysis

Debt Level: MIRM is debt free.

Reducing Debt: MIRM has not had any debt for past 5 years.

Balance Sheet

Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: MIRM has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if MIRM has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.

Discover healthy companies


What is Mirum Pharmaceuticals's current dividend yield, its reliability and sustainability?

Dividend Score


Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Future Dividend Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate MIRM's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate MIRM's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if MIRM's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if MIRM's dividend payments have been increasing.

Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as MIRM has not reported any payouts.

Discover strong dividend paying companies


How experienced are the management team and are they aligned to shareholders interests?


Average management tenure


Chris Peetz (43 yo)





Mr. Christopher Peetz, also known as Chris, serves as Entrepreneur-in-Residence at Frazier Management, L.L.C since May 30, 2017. He joined Frazier on May 30, 2017. He is on the Frazier Life Sciences team (...

CEO Compensation Analysis

Compensation vs Market: Chris's total compensation ($USD4.13M) is about average for companies of similar size in the US market ($USD4.03M).

Compensation vs Earnings: Chris's compensation has increased whilst the company is unprofitable.

Leadership Team

Experienced Management: MIRM's management team is considered experienced (2.8 years average tenure).

Board Members

Experienced Board: MIRM's board of directors are considered experienced (3.1 years average tenure).


Who are the major shareholders and have insiders been buying or selling?

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 5.3%.

Top Shareholders

Company Information

Mirum Pharmaceuticals, Inc.'s employee growth, exchange listings and data sources

Key Information

  • Name: Mirum Pharmaceuticals, Inc.
  • Ticker: MIRM
  • Exchange: NasdaqGM
  • Founded: 2018
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: US$636.194m
  • Shares outstanding: 31.84m
  • Website:

Number of Employees


  • Mirum Pharmaceuticals, Inc.
  • 950 Tower Lane
  • Suite 1050
  • Foster City
  • California
  • 94404
  • United States


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/07/03 00:00
End of Day Share Price2022/07/01 00:00
Annual Earnings2021/12/31

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.